Pharmacokinetics of Curative Tranexamic Acid in Parturients Undergoing Cesarean Delivery.

caesarean section intravenous pharmacokinetics postpartum hemorrhage tranexamic acid

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
06 Mar 2022
Historique:
received: 28 01 2022
revised: 27 02 2022
accepted: 02 03 2022
entrez: 26 3 2022
pubmed: 27 3 2022
medline: 27 3 2022
Statut: epublish

Résumé

The aim of this study was to evaluate the population pharmacokinetics of tranexamic acid (TXA) administered intravenously at a single dose of 0.5 or 1 g in parturients undergoing active hemorrhagic cesarean delivery and to evaluate the influence of patient variables on TXA pharmacokinetics. Subjects from three recruiting centers were included in this PK sub-study if randomized in the experimental group (i.v TXA 0.5 g or 1 g over one minute) of the TRACES study. Blood samples and two urinary samples were collected within 6 h after TXA injection. Parametric non-linear mixed-effect modeling (Monolix v2020R1) was computed. The final covariate model building used 315 blood and 117 urinary concentrations from seventy-nine patients. A two-compartment model with a double first-order elimination from the central compartment best described the data. The population estimates of clearance (CL), central volume of distribution (V1), and half-life for a typical 70 kg patient with an estimated renal clearance of 150 mL/min (Cockroft-Gault) were 0.14 L/h, 9.25 L, and 1.8 h. A correlation between estimated creatinine clearance and CL, body weight before pregnancy, and V1 was found and partly explained the PK variability. The final model was internally validated using a 500-run bootstrap. The first population pharmacokinetic model of TXA in active hemorrhagic caesarean section was successfully developed and internally validated.

Identifiants

pubmed: 35335955
pii: pharmaceutics14030578
doi: 10.3390/pharmaceutics14030578
pmc: PMC8952437
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministère des Solidarités et de la Santé
ID : PHRC n° 14-0032
Organisme : Agence Nationale de Sécurité du Médicament et des Produits de Santé
ID : AAP 15-003

Références

Fundam Clin Pharmacol. 2019 Dec;33(6):670-678
pubmed: 31013357
Antimicrob Agents Chemother. 2014 Jun;58(6):3504-13
pubmed: 24733461
Lancet. 2010 Jul 3;376(9734):23-32
pubmed: 20554319
Eur J Clin Pharmacol. 1981;20(1):65-72
pubmed: 7308275
Blood Coagul Fibrinolysis. 2019 Jan;30(1):1-10
pubmed: 30585835
Lancet. 2016 Oct 8;388(10053):1775-1812
pubmed: 27733286
Eur J Haematol. 2020 Feb;104(2):79-87
pubmed: 31729076
Wellcome Open Res. 2018 Aug 15;3:100
pubmed: 30345385
Eur J Pharm Sci. 2020 Oct 1;153:105486
pubmed: 32717429
Nephron. 1976;16(1):31-41
pubmed: 1244564
Int J Gynaecol Obstet. 2021 Sep;154(3):393-399
pubmed: 33529365
Hypertens Pregnancy. 2009;28(3):243-55
pubmed: 19440935
Trials. 2018 Mar 1;19(1):148
pubmed: 29490682
Int J Endocrinol Metab. 2012 Spring;10(2):486-9
pubmed: 23843808
Crit Care. 2011;15(2):R117
pubmed: 21496253
Br J Anaesth. 2013 Dec;111(6):916-24
pubmed: 23880099
Anesthesiology. 2002 Aug;97(2):390-9
pubmed: 12151929
Lancet Glob Health. 2014 Jun;2(6):e323-33
pubmed: 25103301
Clin Chem. 2007 Apr;53(4):766-72
pubmed: 17332152
Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3
pubmed: 2520314
Trials. 2018 Mar 1;19(1):149
pubmed: 29490690
Br J Anaesth. 2022 Mar;128(3):465-472
pubmed: 34998508
Br J Clin Pharmacol. 2021 Sep;87(9):3531-3541
pubmed: 33576009
Obstet Med. 2021 Mar;14(1):31-34
pubmed: 33995570
Lancet Glob Health. 2018 Jan;6(1):e18-e19
pubmed: 29100880
Anaesthesia. 2018 Jun;73(6):719-729
pubmed: 29411358
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839

Auteurs

Sixtine Gilliot (S)

ULR-7365-Groupe de Recherche sur les Formes Injectables et les Technologies Associées (GRITA), Université de Lille, Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.
Institut de Pharmacie, Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.

Anne-Sophie Ducloy-Bouthors (AS)

ULR-7365-Groupe de Recherche sur les Formes Injectables et les Technologies Associées (GRITA), Université de Lille, Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.
Pôle Anesthésie-Réanimation, Hôpital Huriez, Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.

Florence Loingeville (F)

ULR2694-METRICS-Evaluation des Technologies de Santé et des Pratiques Médicales, Université de Lille, Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.

Benjamin Hennart (B)

Unité Fonctionnelle de Toxicologie, Pôle Biologie Pathologie Génétique, Centre Biologie Pathologie, Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.

Delphine Allorge (D)

Unité Fonctionnelle de Toxicologie, Pôle Biologie Pathologie Génétique, Centre Biologie Pathologie, Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.
ULR 4483-IMPECS-IMPact de l'Environnement Chimique sur la Santé, Faculté de Médecine-Pôle Recherche, Université de Lille, 1 Place de Verdun, F-59045 Lille, France.

Gilles Lebuffe (G)

ULR-7365-Groupe de Recherche sur les Formes Injectables et les Technologies Associées (GRITA), Université de Lille, Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.
Pôle Anesthésie-Réanimation, Hôpital Huriez, Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.

Pascal Odou (P)

ULR-7365-Groupe de Recherche sur les Formes Injectables et les Technologies Associées (GRITA), Université de Lille, Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.
Institut de Pharmacie, Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.

Classifications MeSH